Chemistry:Labetuzumab
From HandWiki
Revision as of 01:08, 17 July 2022 by imported>Steve Marsio (url)
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | carcinoembryonic antigen |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
(what is this?) (verify) |
Labetuzumab (marketed under the trade name CEA-CIDE) is a humanized IgG1 monoclonal antibody for the treatment of colorectal cancer.[1] It selectively binds to carcinoembryonic cell adhesion molecule 5. [2]
Also tried in patients with MTC (medullary thyroid carcinoma) with metastasis.
This drug was developed by Immunomedics, Inc.
References
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN): Labetuzumab". WHO Drug Information 16 (1): 95. 2002. https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl47.pdf?sfvrsn=126d5a68_5&download=true.
- ↑ "labetuzumab-SN-38 immunoconjugate IMMU-130". National Cancer Institute: NCI Dictionaries. National Institutes of Health, U.S. Department of Health and Human Services. http://www.cancer.gov/drugdictionary?cdrid=692828.
Original source: https://en.wikipedia.org/wiki/Labetuzumab.
Read more |